China National Pharmaceutical Group, commonly known as Sinopharm, is a leading player in the pharmaceutical and healthcare industry, headquartered in Beijing, China. Established in 1998, Sinopharm has rapidly expanded its operations across various regions, including Asia, Europe, and Africa, solidifying its position as a global healthcare provider.
The company focuses on the research, development, manufacturing, and distribution of pharmaceuticals, medical devices, and healthcare services. Sinopharm is particularly renowned for its extensive portfolio of vaccines and innovative biopharmaceuticals, which are distinguished by their quality and efficacy.
With a strong market presence, Sinopharm has achieved significant milestones, including being listed among the Fortune Global 500. Its commitment to advancing healthcare solutions continues to drive its reputation as a trusted leader in the pharmaceutical sector.
-17 vs industry average
CHINA NATIONAL PHARMACEUTICAL GROUP’s score of 13 is lower than 31% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at CHINA NATIONAL PHARMACEUTICAL GROUP?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has reduced its overall emissions by 19% since 2018
Reported emissions
No reported emissions data is available for CHINA NATIONAL PHARMACEUTICAL GROUP yet.
CHINA NATIONAL PHARMACEUTICAL GROUP's reported carbon emissions
China National Pharmaceutical Group (CNPG) currently does not have available data on its carbon emissions, as no specific emissions figures have been reported. Consequently, there are no details regarding Scope 1, Scope 2, or Scope 3 emissions, nor any significant reduction targets or achievements.
In the absence of emissions data, it is important to note that CNPG has not publicly committed to any specific climate initiatives or reduction targets. This lack of information may reflect a broader industry context where pharmaceutical companies are increasingly under pressure to disclose their environmental impact and set ambitious climate goals.
As the global focus on sustainability intensifies, it is anticipated that CNPG, like many of its peers, will need to establish clear climate commitments and strategies to address carbon emissions in the future.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
CHINA NATIONAL PHARMACEUTICAL GROUP’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for CHINA NATIONAL PHARMACEUTICAL GROUP yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
CHINA NATIONAL PHARMACEUTICAL GROUP
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project